Novo Nordisk Sued Over Alleged Wegovy Vision Loss Side Effects

A new product liability lawsuit filed in federal court in Pennsylvania alleges that the weight loss medication Wegovy caused a Massachusetts man to suffer permanent vision loss. The complaint, filed by plaintiff John A. Smith on June 5, 2026, names Wegovy manufacturer Novo Nordisk as the defendant. Smith alleges that his use of the drug led to the development of a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can result in irreversible damage to the optic nerve and subsequent vision loss.

Wegovy: A Popular Weight Loss Drug

Wegovy, which contains the active ingredient semaglutide, is a medication primarily prescribed for weight management and obesity treatment. Initially developed as a treatment for type 2 diabetes under the brand name Ozempic, semaglutide has gained popularity due to its effectiveness in promoting weight loss. The drug works by mimicking a hormone that regulates appetite, thereby helping individuals control their food intake and manage their weight.

Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. This class of medications is designed to enhance insulin secretion, reduce appetite, and slow gastric emptying. By doing so, it aids in lowering blood sugar levels and promoting weight loss. However, as semaglutide’s use has expanded, concerns regarding potential side effects of the drug have surfaced, namely gastroparesis (stomach paralysis) and vision-related complications.

Allegations of Vision Loss Linked to Wegovy

John Smith’s lawsuit alleges a troubling connection between Wegovy and the development of NAION, a condition characterized by sudden vision loss due to reduced blood flow to the optic nerve. The complaint states that Smith was prescribed Wegovy – promoted as a safe and effective weight loss solution – in July 2024. By August 2025, he had begun experiencing blurred vision in his left eye, which ultimately led to a diagnosis of NAION.

“As a result of Defendant’s actions and inactions, Plaintiff suffers from severe vision loss in his left eye, which impacts his activities of daily living, including his ability to work,” the Wegovy lawsuit states. “He seeks damages associated with these injuries.”

Symptoms of NAION Vision Loss

NAION-related vision loss can manifest through various symptoms, including:

• Sudden loss of vision in one eye
• Blurred or distorted vision
• Dark spots or shadows in the visual field
• Light sensitivity

These symptoms can occur without warning, making early detection and intervention challenging. Unfortunately, for many individuals, including Smith, the damage caused by NAION is irreversible.

Scientific Evidence Linking Semaglutide to NAION

Recent studies have established a correlation between GLP-1 receptor agonists, such as Wegovy and Ozempic, and an increased risk of developing NAION. Research conducted by reputable institutions, including Harvard Medical School, has indicated that patients using semaglutide may face a significantly higher risk of vision-related complications.

Key Findings from Semaglutide Side Effect Research

A February 2026 study published in JAMA Ophthalmology found that individuals using semaglutide were twice as likely to develop NAION compared to those on alternative diabetes medications.

Another cohort study involving over 400,000 individuals in Denmark diagnosed with type 2 diabetes revealed that those prescribed semaglutide had more than double the risk of developing NAION.

Additional research has suggested that the risk of NAION may be even higher for non-diabetic users taking Wegovy for weight loss.

These findings have raised serious concerns among healthcare professionals and patients alike, prompting calls for greater transparency regarding the potential health risks associated with these medications.

Legal Implications and Ongoing Semaglutide Litigation

Smith’s lawsuit is part of a growing trend of legal actions against Novo Nordisk, with plaintiffs alleging that the drug manufacturer failed to adequately warn patients and healthcare providers about the risks of NAION allegedly associated with Wegovy and Ozempic. Complaints claim that Novo Nordisk prioritized profits over patient safety, resulting in severe and life-altering consequences for individuals like Smith.

As more individuals come forward with similar claims of vision loss and other complications, more than 140 GLP-1 RA NAION lawsuits have already been consolidated into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania. More than 3,800 lawsuits have been consolidated into a separate MDL, covering other injuries allegedly linked to GLP-1 drugs like Ozempic and Wegovy. This consolidation of legal claims allows for coordinated pretrial proceedings and aims to streamline the legal process for individuals with similar complaints.

Pursuing Compensation for NAION Vision Loss, Other Injuries

For individuals like John Smith, the consequences of alleged pharmaceutical drug-related injuries extend beyond physical health. Irreversible vision loss can significantly impact daily activities, employment opportunities, and overall quality of life. As such, many affected individuals are seeking legal recourse to hold Novo Nordisk accountable for their alleged negligence.

As more evidence emerges regarding the potential health risks associated with Wegovy and Ozempic, it is imperative that healthcare providers communicate these alleged risks effectively to their patients. Patients should feel empowered to ask questions and seek clarification about their medications. Understanding the potential side effects and risks associated with medical treatments can help individuals make informed decisions about their health and well-being.